Kiromic BioPharma Inc, a Houston-based biotherapeutics company, was charged by the SEC for failing to report in its form S-1 and 10-Q filings that the FDA had placed clinical holds on two of its experimental cancer treatments. For their roles in the certifying the deficient filings, former CEO Maurizio Chiriva-Internati
SEC charges Kiromic BioPharma for failing to disclose FDA holds
Two former executives were fined, but the company itself will not receive a civil penalty due to its self-reporting.